Portage Biotech Inc. (NASDAQ:PRTG – Get Free Report) was the target of a significant growth in short interest in February. As of February 28th, there was short interest totalling 17,400 shares, a growth of 33.8% from the February 13th total of 13,000 shares. Currently, 10.6% of the shares of the stock are sold short. Based on an average daily volume of 650,300 shares, the days-to-cover ratio is currently 0.0 days.
Institutional Investors Weigh In On Portage Biotech
An institutional investor recently bought a new position in Portage Biotech stock. Citadel Advisors LLC acquired a new position in Portage Biotech Inc. (NASDAQ:PRTG – Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 15,431 shares of the company’s stock, valued at approximately $80,000. Citadel Advisors LLC owned about 1.47% of Portage Biotech as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 13.36% of the company’s stock.
Portage Biotech Stock Performance
Portage Biotech stock traded up $0.12 during mid-day trading on Monday, hitting $4.33. 2,787 shares of the company traded hands, compared to its average volume of 70,666. Portage Biotech has a one year low of $2.10 and a one year high of $23.01. The stock has a market cap of $4.54 million, a price-to-earnings ratio of -0.10 and a beta of 1.29. The stock has a fifty day moving average price of $4.44 and a 200-day moving average price of $4.96.
Portage Biotech Company Profile
Portage Biotech Inc, a clinical stage immune-oncology company, engages in the research and develops pharmaceutical and biotechnology products. Its product pipeline includes PORT-2 for treatment of refractory NSCLC, melanoma, and refractory melanoma that is in phase I and phase II clinical trials; PORT-3, for treatment of solid tumors, which is in phase I clinical trials; PORT-6, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ia clinical trials; PORT-7, an A2AR inhibitor to treat A2A & A2B high solid tumors that is in phase Ib clinical trials; PORT-1, an intratumoral amphiphilic solutions for treatment of advanced soft tissue sarcoma, which is in phase 3 clinical trials; PORT-4, a nanolipogel co-formulations to treat of solid tumors that is in preclinical trials; and PORT-5, a VLP-STING to treat of solid tumors that is in preclinical trials.
Featured Articles
- Five stocks we like better than Portage Biotech
- Pros And Cons Of Monthly Dividend Stocks
- Can TikTok Stock Picks Really Make You Rich?
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- The “Quality” Rotation: Back to Basics Investing
- How to Use the MarketBeat Dividend Calculator
- Occidental Petroleum: 4 Reasons to Love These Prices
Receive News & Ratings for Portage Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portage Biotech and related companies with MarketBeat.com's FREE daily email newsletter.